Janney Montgomery Scott set a $26.00 target price on Collegium Pharmaceutical (NASDAQ:COLL) in a research report released on Tuesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other research analysts have also weighed in on the company. Zacks Investment Research lowered Collegium Pharmaceutical from a buy rating to a hold rating in a research report on Friday, February 2nd. BidaskClub lowered Collegium Pharmaceutical from a buy rating to a hold rating in a research report on Friday, January 26th. Piper Jaffray Companies set a $33.00 target price on Collegium Pharmaceutical and gave the stock a buy rating in a research report on Tuesday, January 23rd. Needham & Company LLC upped their target price on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a buy rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Finally, Jefferies Group upped their target price on Collegium Pharmaceutical to $27.00 and gave the stock a buy rating in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Collegium Pharmaceutical has an average rating of Buy and an average price target of $25.17.

Collegium Pharmaceutical (COLL) opened at $21.43 on Tuesday. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $26.77.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The company had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. During the same period in the prior year, the firm posted ($1.13) EPS. The business’s revenue was up 2814.6% compared to the same quarter last year. sell-side analysts anticipate that Collegium Pharmaceutical will post -2.52 EPS for the current fiscal year.

In other news, CEO Michael Thomas Heffernan sold 50,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the transaction, the chief executive officer now owns 558,987 shares of the company’s stock, valued at approximately $8,681,068.11. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CTO Alison B. Fleming sold 4,029 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the transaction, the chief technology officer now directly owns 28,513 shares in the company, valued at approximately $484,721. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,105,558 shares of company stock worth $19,346,677. Insiders own 25.76% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Voya Investment Management LLC acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at about $125,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Collegium Pharmaceutical by 87.5% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after acquiring an additional 3,500 shares during the last quarter. Nationwide Fund Advisors increased its holdings in shares of Collegium Pharmaceutical by 27.8% during the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after acquiring an additional 2,802 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at about $176,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Collegium Pharmaceutical during the 3rd quarter valued at about $192,000. 82.29% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/07/collegium-pharmaceutical-coll-given-a-26-00-price-target-by-janney-montgomery-scott-analysts.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.